Vistagen Crashes as Fasedienol Phase 3 Trial Misses Primary Endpoint
The company plans further FDA discussions and a strategic pivot to longer-term treatment.
/ 2 items
The company plans further FDA discussions and a strategic pivot to longer-term treatment.
Vistagen Therapeutics stock crashes after fasedienol, its experimental nasal spray for social anxiety disorder, fails to meet primary endpoints in Phase 3 PALISADE-3 trial.